FDA-cleared profile

Cleerly LABS (v2.0)

Cleerly, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.

Clinical role
Deep learning segments and labels coronary arteries and segments lumen and vessel walls for user review and editing; plaque, stenosis and vessel measurements are output from user-editable segmentation and user-placed markers; the CORONARY Report is not the final physician report.
Images and patients
CT/CTA · Heart/Coronary arteries
Key limitation
Keep in mind: Interpolation can appear healthy despite pathology at or below image resolution; users must review source images and use judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Coronary arteries Input: DICOM 3.0-or-later cardiac CT/CCTA images from a CT scanner.
  • Who uses it?Intended users: Trained healthcare professionals.
  • What does the software produce?Output: Interactive CORONARY Report visualizations, segmented/labeled coronary anatomy and plaque/stenosis measurements; report pages may be sent to PACS but are not a final physician report.
  • What is its most important limitation?Key limitation: Interpolation can appear healthy despite pathology at or below image resolution; users must review source images and use judgment.

Clinical takeaway. Clinical role: Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.

Evidence takeaway. Evidence from the reviewed source record: Software verification and production-release regression testing support the submission changes; no new clinical cohort was reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assists trained professionals with coronary-vessel, lumen, vessel-wall, plaque and stenosis visualization and measurements from CCTA; it does not replace clinical judgment.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Deep learning segments and labels coronary arteries and segments lumen and vessel walls for user review and editing; plaque, stenosis and vessel measurements are output from user-editable segmentation and user-placed markers; the CORONARY Report is not the final physician report.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software applies deep learning methodology to identify high quality images, segment and label coronary arteries, and segment lumen and vessel walls. 2D and 3D images are presented to the user for review and manual editing." … "Plaque, stenosis, and vessel measurements are output based on the combination of user-editable segmentation and user-placed stenosis, stent, and CTO markers.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM 3.0-or-later cardiac CT/CCTA images from a CT scanner.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Interactive CORONARY Report visualizations, segmented/labeled coronary anatomy and plaque/stenosis measurements; report pages may be sent to PACS but are not a final physician report.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Patients who underwent coronary CT angiography (CCTA) for evaluation of coronary artery disease (CAD) or suspected CAD; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "and stenosis in patients who underwent Coronary Computed Tomography Angiography (CCTA) for evaluation of CAD or suspected CAD." … "The software is a post-processing tool that aids in determining treatment paths for patients suspected of having coronary artery disease (CAD).". Read from the exact FDA decision document on 2026-11-14.

Intended users
Trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Interpolation can appear healthy despite pathology at or below image resolution; users must review source images and use judgment.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Software verification and production-release regression testing support the submission changes; no new clinical cohort was reported.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification and production-release regression testing support the submission changes; no new clinical cohort was reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05
Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Cleerly LABS v2.0 regulatory verification and regression testing

  • DesignSoftware verification and production-release regression testing.
  • PopulationNo clinical cohort reported.
  • Scopeexact submission
  • Tested versionCleerly LABS v2.0
  • IndependenceIndependence not established

K242338

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
Medicare local coverage policy L39881 (Noridian, MAC jurisdictions J-E and J-F) covers AI-enabled coronary plaque analysis from an already completed and interpreted CCTA for stable or acute chest pain with no known coronary disease when the CCTA is intermediate risk or CAD-RADS 1 to 3 and acute coronary syndrome evaluation is negative or inconclusive. It requires FDA cleared or approved software and does not name any product. The related billing article lists CPT 75577 (added effective 2026-01-01, replacing Category III codes 0623T-0626T). This is a regional service-level policy, not a determination that this exact product, version, site or claim is covered or paid. No payment amount was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

75577

Service-level local coverage policy found (Noridian JE/JF LCD L39881); product-specific coverage and payment not established

Medicare (Noridian Healthcare Solutions MACs, jurisdictions J-E and J-F) · Noridian JE and JF states (California, Nevada, Hawaii, American Samoa, Guam, Northern Mariana Islands, Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming); other MAC jurisdictions not reviewed · Effective 2026-01-01

Code effective date comes from the billing article revision. LCD requires FDA cleared or approved software but names no product. Does not prove eligibility for a particular product version, patient, indication, site or claim; no payment amount reviewed.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 3.0-or-later cardiac CT/CCTA images from a CT scanner.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Cleerly LABS v2.0: K242338 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Cleerly LABS is client-server software accessed through Chrome and integrates with a secured network server; current vendor instructions describe manual upload of zipped CCTA DICOM files to the customer portal.

    Scope: Product family. Upload instructions are family-level workflow context, not a version-2.0 universal interface guarantee.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · Cleerly LABS v2.0: K242338 clearance and 510(k) summary · Cleerly manual upload instructions

  3. AI processing

    Source context, not route validation: Client-server architecture is described; hosting location and commercial deployment topology were not established.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · Cleerly LABS v2.0: K242338 clearance and 510(k) summary

  4. Returned objects

    Source context, not route validation: Interactive CORONARY Report visualizations, segmented/labeled coronary anatomy and plaque/stenosis measurements; report pages may be sent to PACS but are not a final physician report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · Cleerly LABS v2.0: K242338 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Interactive CORONARY Report visualizations, segmented/labeled coronary anatomy and plaque/stenosis measurements; report pages may be sent to PACS but are not a final physician report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · Cleerly LABS v2.0: K242338 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Client-server architecture is described; hosting location and commercial deployment topology were not established.
  • Exact FDA submission
  • Checked 2026-09-05
Integration
Cleerly LABS is client-server software accessed through Chrome and integrates with a secured network server; current vendor instructions describe manual upload of zipped CCTA DICOM files to the customer portal.
  • Product family
  • Checked 2026-09-05

Upload instructions are family-level workflow context, not a version-2.0 universal interface guarantee.

Manual CCTA upload workflow

Current vendor instructions describe portal upload of zipped CCTA DICOM files and a generated Cleerly ID.

product family · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242338
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Stored trial metadata is a randomized personalized plaque-management study sponsored by Cleerly; it does not identify Cleerly LABS v2.0 and was retained only as an unreviewed family lead, not promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor instructions for use, literature index, trial registry, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact product version

    No public quote was located in reviewed material.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact product version

    A secured-network description is not a scoped security attestation.

  • Installation timeline: Not yet reviewed
  • Training: Not publicly available - checked 2026-09-05 - Exact product version
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

10 sources - 3 history items

Source ledger

  1. K242338 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Cleerly LABS (v2.0) model card (K242338)

    American College of Radiology - Published 2026-08-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Cleerly LABS v2.0: K242338 clearance and 510(k) summary

    US Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, implementation, evidence

  8. Cleerly manual upload instructions

    Cleerly - Accessed 2026-09-05

    Scope: product_family_implementation

  9. CMS Medicare Coverage Database LCD L39881: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

  10. CMS Medicare Coverage Database Billing and Coding Article A59769: AI-QCT/AI-CPA

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

Research history

  1. K242338 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252029

AI-CVD

HeartLung Corporation

Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.

Modality
CT/CTA
Anatomy
Chest, abdomen, heart, lungs, liver, aorta, pulmonary artery, bone, muscle, and fat
Decision
2025-12-19
FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history